Full Text View
Tabular View
No Study Results Posted
Related Studies
Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage
This study has been completed.
Study NCT00009620   Information provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First Received: February 1, 2001   Last Updated: February 21, 2007   History of Changes

February 1, 2001
February 21, 2007
January 1993
 
 
 
Complete list of historical versions of study NCT00009620 on ClinicalTrials.gov Archive Site
 
 
 
Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage
Randomized Clinical Trial of Antenatal Phenobarbital in the Prevention of Neonatal Intracranial Hemorrhage

This large randomized trial tested whether phenobarbital given to a pregnant woman about to deliver a premature infant would prevent brain injuries in their newborns. Women with 24 to 32 week fetuses who were in preterm labor and were expected to deliver within 24 hrs were randomized to phenobarbital or usual care. They were treated until they deliver or the fetus reaches 33 wks gestation. Babies were followed until discharge and evaluated at 18-22 mos corrected age for neurodevelopmental outcome.

The administration of phenobarbital to pregnant women before delivery has been thought to decrease the frequency of intracranial hemorrhage in preterm infants. To evaluate this potential neuroprotective therapy further, we determined the effect of antenatal administration of phenobarbital on the frequency of neonatal intracranial hemorrhage and early death. Women who were 24 to 33 weeks pregnant and who were expected to deliver their infants within 24 hours were randomly assigned to receive either intravenous phenobarbital (10 mg/kg body weight) or placebo, followed by maintenance doses until delivery or 34 wks gestation. Infants less than 34 wks at birth underwent serial cranial ultrasonography to detect the presence of intracranial hemorrhage. The sample size of 1038 pregnancies was based on an intracranial hemorrhage rate of 20 percent in the placebo and less than 12 percent in the phenobarbital group; 90 percent power; a 5 percent two-tailed type 1 error; and an 8 percent noncompliance rate. The twin with the highest grade of intracranial hemorrhage was included.

Degree of maternal sedation was evaluated after administration of study drug. Neonatal ultrasound exams were performed at 3-5 days, 10-14 days, and 38-42 wks postmenstrual age; neonatal medications were recorded during the first week of life; treatments, and outcomes were recorded through death, discharge, or 120 days, whichever occurred first. Neurodevelopmental outcome was evaluated at 18-22 months corrected age by certified examiners masked to treatment status.

Phase III
Interventional
Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
  • Intracranial Hemorrhage
  • Brain Injury
  • Brain Hemorrhage
Drug: phenobarbital
 
Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA, Korones SB, Stevenson DK, Donovan EF, Stoll BJ, Fanaroff AA, Oh W. The effect of antenatal phenobarbital therapy on neonatal intracranial hemorrhage in preterm infants. N Engl J Med. 1997 Aug 14;337(7):466-71.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
1038
February 1995
 

Inclusion Criteria:

  • Admission to a high risk perinatal unit or labor and delivery unit;
  • 24 to 32 completed weeks gestation;
  • Expected delivery within 24 hrs;
  • Preterm labor or no labor with planned delivery for maternal-fetal indications;

Exclusion Criteria:

  • Multiple gestation beyond twins
Female
 
No
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00009620
 
NICHD-1000
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
 
Principal Investigator: Seetha Shankaran, MD Wayne State University
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
January 2001

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP